Indian Immunologicals Limited

Indian Immunologicals Limited (IIL) is a prominent biotechnology company based in Hyderabad, Telangana, India. Established in 1982 by the National Dairy Development Board (NDDB), IIL was incorporated as a public limited company in 1999 under the Corporate Identification Number (CIN) U72200TG1999PLC032666. The company specializes in the development and manufacturing of vaccines and other immunobiological products, serving both human and veterinary sectors. IIL's product portfolio includes over 150 items, with a significant presence in the Indian market and exports to more than 50 countries.

As a subsidiary of the NDDB, IIL operates with a mission to make biotechnology in healthcare affordable and accessible. The company's authorized capital is ₹400 crore, with a paid-up capital of ₹54 crore. IIL employs between 1,000 and 5,000 individuals, reflecting its substantial operational scale. The company's official website is www.indimmune.com.

IIL operates multiple manufacturing facilities across India, each specializing in different aspects of vaccine production. The Gachibowli-Hyderabad facility is dedicated to the production of vaccines, while the Karakapatla-Hyderabad facility focuses on animal health formulations and human vaccines. Additionally, IIL has a facility in Ooty, Tamil Nadu, which exclusively produces the human anti-rabies vaccine, "Abhayrab." These facilities are equipped with state-of-the-art technology and adhere to stringent quality control measures to ensure the safety and efficacy of their products.

The leadership team at Indian Immunologicals Limited is headed by Managing Director Dr. K. Anand Kumar, who has been instrumental in steering the company's strategic direction and growth. The Chief Financial Officer (CFO) is G. Rajasekhar, responsible for overseeing the company's financial operations. Other key executives include Vice President & Head of R&D Rajendra Lingala, Vice President of Human Resources Mohan Rao, and Head of Marketing HR & L&D Narendra Agrawal. These leaders collectively contribute to IIL's mission of providing affordable and accessible biotechnology solutions in healthcare.

Indian Immunologicals Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals for its products in these regions, ensuring compliance with international standards. For instance, IIL's facility in Ooty, Tamil Nadu, is WHO-GMP certified, indicating adherence to the World Health Organization's Good Manufacturing Practices. This certification facilitates the export of IIL's products to various countries, including those in the European Union and other regulated markets. Additionally, IIL's subsidiary, Pristine Biologicals Ltd in New Zealand, is involved in the production of serum used in the manufacture of vaccines, further expanding its international footprint.

IIL has strategically expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are exported to more than 50 countries, with a focus on regions such as the Middle East, Asia, Africa, and Central and Latin America. The World Health Organization's prequalification of IIL's products has been instrumental in facilitating access to these markets, as it ensures that the company's vaccines meet international standards of quality, safety, and efficacy. This prequalification is a critical factor in gaining acceptance and trust in emerging markets, where regulatory scrutiny is stringent.

Indian Immunologicals Limited has adopted a diversified geographic strategy to mitigate concentration risk and enhance its global presence. By exporting to over 50 countries, IIL has reduced its dependence on any single market, thereby spreading its risk and capitalizing on growth opportunities worldwide. The company's strategic direction focuses on expanding its footprint in both developed and emerging markets, leveraging its WHO-GMP certified facilities and a robust product portfolio to meet diverse healthcare needs. This approach aligns with IIL's mission to make biotechnology in healthcare affordable and accessible globally.

Indian Immunologicals Limited has made significant strides in the U.S. market, with its products being registered with the U.S. Food and Drug Administration (FDA). The company's facilities adhere to FDA standards, ensuring that its products meet the rigorous requirements for safety and efficacy. IIL has also filed Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs) with the FDA, facilitating the approval process for its products in the U.S. market. The company's commitment to quality is further demonstrated by its inspection history, which reflects compliance with FDA regulations. These efforts underscore IIL's dedication to expanding its presence in the U.S. and other regulated markets.

Indian Immunologicals Limited's commitment to quality is evident through its adherence to international standards. The company's facilities, including the one in Ooty, Tamil Nadu, are WHO-GMP certified, indicating compliance with the World Health Organization's Good Manufacturing Practices. This certification is crucial for exporting products to the European Union, as it ensures that IIL's vaccines meet the stringent quality standards required by the European Medicines Agency (EMA). Additionally, IIL's products are prequalified by the WHO, further facilitating access to global markets.

In India, Indian Immunologicals Limited operates under the regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO). The company's manufacturing facilities are licensed by the CDSCO, ensuring compliance with national standards for drug manufacturing. IIL also obtains necessary approvals from state drug controllers and export No Objection Certificates (NOCs) to facilitate the export of its products. These regulatory compliances are essential for maintaining the quality and safety of IIL's products in both domestic and international markets.

As of March 2026, there have been no publicly reported Form 483 observations, warning letters, or import alerts issued against Indian Immunologicals Limited by the U.S. Food and Drug Administration (FDA). This indicates that the company's manufacturing facilities are in compliance with FDA regulations, reflecting positively on its commitment to quality and regulatory adherence. Maintaining a clean regulatory record is crucial for sustaining trust and ensuring uninterrupted access to key markets.

Indian Immunologicals Limited operates in a competitive landscape with several key players in the vaccine manufacturing sector. In the Indian market, IIL faces competition from companies such as Serum Institute of India and Bharat Biotech, which also have significant market shares in vaccine production. Globally, IIL competes with multinational corporations like GlaxoSmithKline and Sanofi Pasteur. Despite the competition, IIL has managed to secure a substantial market share in various segments, including pediatric and rabies vaccines, by focusing on quality, affordability, and accessibility. The company's strategic partnerships and adherence to international standards have further bolstered its position in the market.

Indian Immunologicals Limited distinguishes itself through several key differentiators:

• Affordability and Accessibility: IIL's mission to make biotechnology in healthcare affordable and accessible has led to the development of cost-effective vaccines, particularly for underserved populations.

• Regulatory Compliance: The company's adherence to international standards, including WHO-GMP certification and WHO prequalification, ensures that its products meet global quality benchmarks.

• Comprehensive Product Portfolio: With over 150 products, IIL offers a diverse range of vaccines and immunobiologicals, catering to both human and veterinary needs.

• Strategic Partnerships: Collaborations with international organizations and research institutions enhance IIL's research and development capabilities, leading to innovative product offerings.

Indian Immunologicals Limited's current strategic direction focuses on expanding its presence in both domestic and international markets by leveraging its WHO-GMP certified facilities and a robust product portfolio. The company's emphasis on research and development, coupled with strategic partnerships, positions it well to introduce new vaccines and immunobiologicals to meet emerging healthcare needs. Looking ahead, IIL aims to strengthen its position in the global vaccine market by adhering to international quality standards and maintaining a commitment to affordability and accessibility.

Indian Immunologicals Limited has demonstrated a strong track record as a supplier of vaccines and immunobiologicals. The company's export volume of $29.1 million USD across 581 shipments indicates a consistent and reliable supply